CAJ | 학술논문

目的：探讨拉米夫定抗病毒治疗慢性乙型肝炎的临床疗效。方法选择2012年1月～2012年12月浙江省湖州市德清县人民医院收治的78例慢性乙型肝炎患者作为观察对象，随机分为实验组（n=39）和对照组（n=39）。对照组采用恩替卡韦治疗，实验组采用拉米夫定治疗。对比2组治疗6周、12周、18周、24周时乙型肝炎病毒阴转率、乙型肝炎病毒表面抗原（hepatitis B surface antigen，HBsAg）阴转率以及丙氨酸氨基转移酶（Alamine aminotransferase，ALT）复常率。结果对照组治疗6周、12周、18周、24周时乙型肝炎病毒转阴率、ALT复常率均优于实验组，差异均具有显著性（P<0.05）；2组治疗6周、12周、18周、24周时HBsAg 阴转率无显著性差异。结论拉米夫定抗病毒治疗慢性乙型肝炎临床疗效尚可，和恩替卡韦相比还是有一定差距，但是拉米夫定具有更合适的价格，对广大患者来说药物经济学优势比恩替卡韦要好，临床应用时需结合患者实际情况选择用药。
목적：탐토랍미부정항병독치료만성을형간염적림상료효。방법선택2012년1월～2012년12월절강성호주시덕청현인민의원수치적78례만성을형간염환자작위관찰대상，수궤분위실험조（n=39）화대조조（n=39）。대조조채용은체잡위치료，실험조채용랍미부정치료。대비2조치료6주、12주、18주、24주시을형간염병독음전솔、을형간염병독표면항원（hepatitis B surface antigen，HBsAg）음전솔이급병안산안기전이매（Alamine aminotransferase，ALT）복상솔。결과대조조치료6주、12주、18주、24주시을형간염병독전음솔、ALT복상솔균우우실험조，차이균구유현저성（P<0.05）；2조치료6주、12주、18주、24주시HBsAg 음전솔무현저성차이。결론랍미부정항병독치료만성을형간염림상료효상가，화은체잡위상비환시유일정차거，단시랍미부정구유경합괄적개격，대엄대환자래설약물경제학우세비은체잡위요호，림상응용시수결합환자실제정황선택용약。
Objective To evaluate the clinical efifcacy of lamivudine in chronic hepatitis B antiviral therapy. Methods 78 cases with chronic hepatitis B patients from January 2012 to December 2012 collected in People's Hospital of Deqing County were observed and randomly divided into experimental group and control group, 39 cases in each group. Control group were treated with entecavir , and experimental group with lamivudine. The negative rate of hepatitis B virus, hepatitis B virus surface antigen (hepatitis B surface antigen, HBsAg) seroconversion rates and alanine aminotransferase (Alamine aminotransferase, ALT) recovery rate after 6 weeks, 12 weeks , 18 weeks , 24 weeks of the two groups were compared. Results The negative rate of hepatitis B virus, ALT recovery rates in control group after 6 weeks, 12 weeks , 18 weeks, 24 weeks treatment were better than experimental group , the differences were statistically signiifcant(P<0.05). There was no signiifcant differences in the rate of HBsAg seroconversion at week 6 weeks, 12 weeks, 18 weeks, 24 weeks between two groups. Conclusion Lamivudine antiviral ,has acceptable clinical efifcacy in treatment for chronic hepatitis B, and still has a certain gap with entecavir, but it has an appropriate price, which may be more suitable for patients in economic. So choose which medicine in clinical application should be in combination with the practical situation of patients.